Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

Key facts

Study ID

NCT03262389

Run by

Michael C Roarke, MD

People needed

10

Starts

2017-09-19

Expected to finish

2019-11-23

Last updated by the study team

2021-03-16

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
• Patients who have undergone standard of care workup
• 300 pounds or less
• Can provide informed consent
• Scheduled for a clinically indicated F-18 FDG PET scan
• English speaking

You may not qualify if…

• Pregnant, breast feeding
• Concurrent active non-multiple myeloma malignancy
• Contraindication to PET MRI
• Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.